Key result
Adding empagliflozin to standard care cuts CV deaths ~30% over 3 years.
Answers are grounded in this paper and cite their sources.
AIM: To perform a model-based analysis of the short- and long-term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden. MATERIALS AND METHODS: The validated Institute for Health Economics Diabetes Cohort Model (IHE-DCM) was used to estimate health benefits and a 3-year budget impact, and lifetime costs per quality-adjusted life years (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n = 131 412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results. RESULTS: Over 3 years, SoC with empagliflozin (100% implementation) versus SoC before empagliflozin resulted in 7700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 15% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost-effectiveness ratio of 16 000 EUR per QALY versus SoC before empagliflozin. CONCLUSIONS: Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even from a short-term perspective.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (2022) studied Type 2 diabetes and established cardiovascular disease (n=131,412). Empagliflozin added to standard of care vs. Standard of care before empagliflozin was evaluated on Health benefits (life years gained, cardiovascular deaths, heart failure, QALYs) and budget impact/cost-effectiveness (30% reduction in CV deaths; 28% reduction in heart failures; ICER 16,000 EUR/QALY). Adding empagliflozin to standard of care reduced CV deaths by 30% and heart failure by 28% over 3 years, yielding 0.37 QALYs/person (ICER 16,000 EUR/QALY).
Synapse has enriched 10 related papers. Consider them for comparative context: